

# APTUS PHARMA LIMITED

---

Date: 09.06.2026

To,  
**The BSE Ltd**  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai – 400001

**SECURITY CODE: 544529**  
**SCRIPT SYMBOL: APPL**

Dear Sir / Madam,

**Sub: Prior Intimation of Board Meeting to be held on Friday, June 12, 2026.**

**Ref:** Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) and intimation regarding closure of trading window.

Pursuant to Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI LODR Regulations"), we hereby give prior intimation that a Meeting of the Board of Directors of [Name of the Company] (hereinafter referred to as "the Company") is scheduled to be held on Friday, 12th June, 2026 at 4:00 p.m. at the corporate office of the Company situated at Shri 1st Floor Opp Satyasai Heart Hospital, Narayan Nagar Kalawad Road, Kankot, Rajkot, Gujarat, India, 360005, inter alia, to consider and deliberate upon the following proposed agenda item:

**I. To consider, evaluate and deliberate upon the proposal for raising of funds through:**

(a) issuance of equity shares and / or any other eligible securities by way of Preferential Allotment, in accordance with the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations"), the Companies Act, 2013 and rules framed thereunder, and other applicable laws and regulations, subject to such approvals, permissions and sanctions of the shareholders of the Company and / or regulatory and statutory authorities as may be required; and

(b) Borrowings from banks / financial institutions / other lenders.

**II. To consider and, if thought fit, to authorize the Managing Director of the Company to**

(a) identify, evaluate and interact with prospective investor(s) / proposed allottee(s) in connection with the aforesaid proposed preferential allotment, and to finalize and place before the Board of Directors, at a subsequent meeting, the list of proposed

---

**Regd. Address:** Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi,  
Ahmedabad, Gujarat – 382427, India

Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com

CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM

# APTUS PHARMA LIMITED

---

allottee(s) along with all requisite details as prescribed under the SEBI ICDR Regulations and the Companies Act, 2013, for consideration and approval of the Board.

- (b) identify and approach prospective lenders for the borrowing requirements at the best available terms — and to report back to the Board.

### III. Intimation of Closure of Trading Window

Further to the above, and in terms of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ("SEBI PIT Regulations"), as amended, read with the Company's Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives framed thereunder ("Code of Conduct"), the Trading Window for dealing in the securities of the Company stands closed for all Designated Persons and their Immediate Relatives with effect from 09th June, 2026 (5:00 p.m.), i.e., from the date and time of this intimation, and shall remain closed until the expiry of 48 (forty-eight) hours after the outcome of the aforesaid Board Meeting is disseminated to the Stock Exchange(s) in terms of Regulation 30 of the SEBI LODR Regulations.

All Designated Persons of the Company and their Immediate Relatives are hereby informed and directed not to trade in the securities of the Company during the aforesaid period of closure of the trading window.

### IV. Note

It may please be noted that this intimation pertains only to the consideration of the aforesaid proposal in principle at the exploratory stage. The specific details of the proposed preferential allotment including, inter alia, the quantum/amount of funds to be raised, the number of securities proposed to be issued, the identity of the proposed allottee(s), the issue price, and all other terms and conditions thereof, shall be finalized and disclosed to the Stock Exchange(s) in accordance with the applicable provisions of the SEBI LODR Regulations and SEBI ICDR Regulations, at the appropriate stage and in the manner prescribed thereunder.

Kindly take the above on record.

**Thanking You,**

**Yours faithfully,  
For Aptus Pharma Limited**

---

**Tejash Hathi  
Managing Director  
DIN: 03151221**

---

**Regd. Address:** Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi,  
Ahmedabad, Gujarat – 382427, India

Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com

CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM